The efficacy and safety profile of avutometinib in combination with defactinib support this combination as a potential standard of care for recurrent LGSOC. A randomized phase 3 study of avutometinib and defactinib versus investigator's choice of therapy for women with recurrent LGSOC is currently enrolling (RAMP301; ClinicalTrials.gov identifier: NCT06072781).
No takes yet. Share an insight, caveat, or question.
Banerjee et al. (2025) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: